MAPT and Alzheimer disease: The researchers monitored the following outcomes in patients at least 60 years of age with early-stage AD or MCI: clinical progression of dementia [Clinical Dementia Rating (CDR) sum-of-boxes (SB) score]; cognitive performance; brain magnetic resonance imaging (MRI); and various chemicals measured in the blood and cerebrospinal fluid (such as CSF A42, tau, p181-tau, and plasma A42/A40).